Medical Costs of Prostate Cancer Care in Four Reference Oncology Centers in Colombia

In Colombia, prostate cancer ranks first in incidence and second in cancer-related mortality among men (1). It is a condition of great importance and concern, as its incidence rate continues to rise—mainly due to increased life expectancy, screening programs, and improved diagnostic capabilities.
Based on this background, it is especially relevant to study the potential cost savings that could be generated in the health system if new drugs were introduced for the treatment of prostate cancer, particularly in the metastatic hormone-sensitive stage and the metastatic castration-resistant stage, as these are the ones that generate the highest costs.
This multicenter study focuses on evaluating the potential cost savings associated with the use of darolutamide in patients with metastatic hormone-sensitive prostate cancer, using a theoretical comparative model. Based on the estimated clinical efficacy in progression-free probability from the ARANOTE study, the model simulates treated and untreated patients over a five-year period and calculates the accumulated avoided costs.
If you’d like, I can help you turn this into a formal abstract or summary for publication or presentation. Just say the word!

To estimate and describe the direct costs of prostate cancer across different stages, and the potential reduction in direct costs due to non-progression to the metastatic castration-resistant stage in hormone-sensitive metastatic patients treated with darolutamide, based on a cohort of patients managed at the Centro Radio Oncológico del Caribe, Uroexpertos (Urological Center of Medellín, Colombia), Hospital Universitario Mayor Méderi (Bogotá, Colombia), and Fundación Valle del Lili (Cali, Colombia) during 2021–2024.

It is expected to obtain a characterization of the patients and a description of the average direct medical cost of prostate cancer across different stages, especially in metastatic stages. Additionally, the study aims to estimate the expected avoided costs from treatment with darolutamide in combination therapy in hormone-sensitive metastatic patients, given that they do not progress to the metastatic castration-resistant stage, based on the clinical efficacy of the drug.
If you’d like, I can help you turn this into a formal research abstract or a summary for a grant proposal. Just let me know what format you're aiming for!